page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Cimetadine (Tagamet)

Category:

  • Gastrointestinal

Description:

  • Antiulcer agent (H-2 receptor antagonist)

Indications:

  • Short term treatment of duodenal and benign gastric ulcers

  • Erosive gastroesophageal reflux disease (GERD)

  • Pathological hypersecretory conditions (Zollinger-Ellison syndrome, systemic mastocytosis, endocrine adenomas)

  • As part of multiple drug regiment to eradicate Helicobacter pylori in peptic ulcers

Drug Interactions:

  • Increased concentrations of interacting drugs with potential for toxicity: 

    • benzodiazepines

    • calcium channel blockers

    • carbamazepine

    • clozapine

    • cyclic antidepressants

    • glyburide

    • lomustine

    • melphalan

    • narcotic analgesics

    • nicotine

    • phenytoin

    • quinidine

    • tacrine

    • theophylline

    • tolbutamide

    • warfarin

  • Reduced concentrations of interacting drugs:

    • ketoconazole

    • cefuroxime

    • cefpodoxime

Precautions:

  • Pregnancy category B; excreted in breast milk

  • Smoking decreases effectiveness of cimetadine

  • Organic brain syndrome, hepatic disease, renal disease, elderly

Adverse Reactions (Side Effects):

  • Central Nervous System: anxiety, confusion, depression, dizziness, headache, psychosis, seizures, tremors, weakness

  • Cardiovascular: bradycardia, tachycardia

  • Gastrointestinal: abdominal cramps, diarrhea, jaundice, paralytic ileus

  • Genitourinary: Galactorrhea, gynecomastia, impotence

  • Hematological: Agranulocytosis, aplastic anemia, neutropenia, thrombocytopenia

  • Skin: Alopecia, exfoliative dermatitis, flushing rash, sweating, urticaria

Dosage:

Administered orally, intravenously, or intramuscularly

  • Treatment

    • PO 300mg four times daily with meals for 8 weeks or 400mg twice daily or 800mg at bedtime. After 8 weeks, give 300-400mg at bedtime only

    • IV bolus 300mg/20ml 0.9% NaCl over 1-2 minutes every 6 hours

    • IV INF 300mg/50ml D5W over 15-20 minutes every 6 hours

    • Continuous IV INF 37.5mg/hr (900mg/day)

    • IM 300mg every 6 hours not to exceed 2400mg daily.

  • Prophylaxis of duodenal ulcer: 

    • 400mg at bedtime

  • GERD: 

    • PO 800mg twice daily or 400mg four times daily for 12 weeks

 

 

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site